Mice expressing BCL2 under the control of the IGH enhancer (Eμ) have increased accumulation of BCL2 protein in B cells, dramatically increased numbers of mature B cells and GC B cells, and develop low-incidence pre-B lymphomas, immunoblastic lymphomas and plasmacytomas [31–34]. The gene discussed is BCL2; the disease is plasmacytoma.